Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indivior Pharmaceuticals Inc (INDV)

Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Indivior Pharmaceuticals Inc 10710 Midlothian Turnpike Suite 125 North Chesterfield VA 23235 USA

www.indivior.com Employees: 838 P: 804-379-1040

Sector:

Medical

Description:

Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 3,736,909
Enterprise Value, $K 3,860,909
Shares Outstanding, K 121,922
Float, K 121,922
% Float 100.00%
Short Interest, K 12,191
Short Float 10.00%
Days to Cover 3.05
Short Volume Ratio 0.58
% of Institutional Shareholders 60.33%

Financials:

Annual Sales, $ 1,239 M
Annual Net Income, $ 210,000 K
Last Quarter Sales, $ 357,000 K
Last Quarter Net Income, $ 103,000 K
EBIT, $ 262,000 K
EBITDA, $ 282,000 K

Growth:

1-Year Return 220.06%
3-Year Return 82.88%
5-Year Return 250.29%
5-Year Revenue Growth 91.50%
5-Year Earnings Growth 525.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.82 on 02/26/26
Next Earnings Date 04/23/26 [--]
Earnings Per Share ttm 2.46
EPS Growth vs. Prev Qtr 13.89%
EPS Growth vs. Prev Year 156.25%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 10/11/22

INDV Ratios

Ratio
Price/Earnings ttm 12.39
Price/Earnings forward 9.91
Price/Earnings to Growth N/A
Return-on-Equity % -148.76%
Return-on-Assets % 23.14%
Profit Margin % 16.95%
Debt/Equity -3.26
Price/Sales 3.00
Price/Cash Flow 11.21
Price/Book N/A
Book Value/Share -0.78
Interest Coverage 6.31
60-Month Beta 0.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.